中华风湿病学杂志
中華風濕病學雜誌
중화풍습병학잡지
CHINESE JOURNAL OF RHEUMATOLOGY
2010年
5期
301-304
,共4页
裘昊旻%张舒%薛愉%张文宏%姜亭%白凤敏%何东仪%邹和建
裘昊旻%張舒%薛愉%張文宏%薑亭%白鳳敏%何東儀%鄒和建
구호민%장서%설유%장문굉%강정%백봉민%하동의%추화건
结核菌素试验%风湿性疾病%潜伏结核%生物制剂
結覈菌素試驗%風濕性疾病%潛伏結覈%生物製劑
결핵균소시험%풍습성질병%잠복결핵%생물제제
Tuberculin test%Rheumatic diseases%Latent tuberculosis infection%Biologic agent
目的 比较T细胞酶联免疫斑点法(TSPOT)与结核菌素纯蛋白衍生物(TB-PPD)试验对风湿病患者潜伏结核感染(LTBI)的诊断价值.方法 对260例明确诊断的风湿病患者进行LTBI的筛查.包括询问病史、胸部X线片、PPD试验及应用TSPOT-TB试剂盒对血液标本进行结核分枝杆菌(Mtb)特异性T细胞应答的检测,同时对所有病例进行联合分析.结果 TSPOT检测阳性率24.1%,PPD试验阳性率为39.4%,两者一致率为61.0%.其中PPD阴性/TSPOT阳性29例,PPD阳性/TSPOT阴性67例.卡介苗(BCG)接种史/既往结核病史的患者PPD试验的阳性率显著增高(P<0.05/P<0.01),但两者在TSPOT检测的阳性率上差异无统计学意义(P>0.05.其中127例患者使用生物制剂,9例使用异烟肼预防抗结核治疗,27例因PPD或TSPOT阳性放弃生物制剂治疗.TSPOT(-)PPD(++)的23例患者均在未预防抗结核下按计划接受了生物制剂治疗,上述患者在随访6~18个月期间尚无活动性结核发生.结论 TSPOT技术可能对风湿病(尤其拟接受生物制剂)患者LTBI的诊断提供帮助.
目的 比較T細胞酶聯免疫斑點法(TSPOT)與結覈菌素純蛋白衍生物(TB-PPD)試驗對風濕病患者潛伏結覈感染(LTBI)的診斷價值.方法 對260例明確診斷的風濕病患者進行LTBI的篩查.包括詢問病史、胸部X線片、PPD試驗及應用TSPOT-TB試劑盒對血液標本進行結覈分枝桿菌(Mtb)特異性T細胞應答的檢測,同時對所有病例進行聯閤分析.結果 TSPOT檢測暘性率24.1%,PPD試驗暘性率為39.4%,兩者一緻率為61.0%.其中PPD陰性/TSPOT暘性29例,PPD暘性/TSPOT陰性67例.卡介苗(BCG)接種史/既往結覈病史的患者PPD試驗的暘性率顯著增高(P<0.05/P<0.01),但兩者在TSPOT檢測的暘性率上差異無統計學意義(P>0.05.其中127例患者使用生物製劑,9例使用異煙肼預防抗結覈治療,27例因PPD或TSPOT暘性放棄生物製劑治療.TSPOT(-)PPD(++)的23例患者均在未預防抗結覈下按計劃接受瞭生物製劑治療,上述患者在隨訪6~18箇月期間尚無活動性結覈髮生.結論 TSPOT技術可能對風濕病(尤其擬接受生物製劑)患者LTBI的診斷提供幫助.
목적 비교T세포매련면역반점법(TSPOT)여결핵균소순단백연생물(TB-PPD)시험대풍습병환자잠복결핵감염(LTBI)적진단개치.방법 대260례명학진단적풍습병환자진행LTBI적사사.포괄순문병사、흉부X선편、PPD시험급응용TSPOT-TB시제합대혈액표본진행결핵분지간균(Mtb)특이성T세포응답적검측,동시대소유병례진행연합분석.결과 TSPOT검측양성솔24.1%,PPD시험양성솔위39.4%,량자일치솔위61.0%.기중PPD음성/TSPOT양성29례,PPD양성/TSPOT음성67례.잡개묘(BCG)접충사/기왕결핵병사적환자PPD시험적양성솔현저증고(P<0.05/P<0.01),단량자재TSPOT검측적양성솔상차이무통계학의의(P>0.05.기중127례환자사용생물제제,9례사용이연정예방항결핵치료,27례인PPD혹TSPOT양성방기생물제제치료.TSPOT(-)PPD(++)적23례환자균재미예방항결핵하안계화접수료생물제제치료,상술환자재수방6~18개월기간상무활동성결핵발생.결론 TSPOT기술가능대풍습병(우기의접수생물제제)환자LTBI적진단제공방조.
Objective To compare the efficacy of the conventional PPD skin test and a new enzymelinked immunospot assay(TSPOT-TB)for diagnosing latent tuberculosis infection(LTBI)in patients with rheumatic diseases.Methods Two hundred and sixty rheumatic patients were enrolled,and all were screened for LTBI based on clinical history,chest X-ray,PPD skin test or TSPOT.Results The positive rate of TSPOT assay was 24.1%and that of PPD skin test was 39.4%.The overall concordance rate between the 2tests was 61.0%.Among PPD negative patients (n=149).29 were TSPOT(+)(19.5%).Among PPD(+)patients(n=98),69 were TSPOT(-)(70.0%).The patients who got BCG vaccination or had history of tuberculosis infection showed a significantly higher rate of positive result of PPD skin test than those who did not (P<0.05 or P<0.01).While in TSPOT assay,the BCG vaccination or history of tuberculosis infection did not show influence on TSPOT results(P>0.05).Of the 127 patients who received biological agents after screening for LTBI,9 patients were pretreated with isoniazide.Twenty-seven patients stopped biological agent treatment because of the positive results of PPD or TSPOT.Twenty three patients who had positive PPD but negative TSPOT results received biological agent treatment without isoniazide,and none of them developed active tubereulosis after 6 to 18 months of follow-up.Conclusion BCG vaccination affects the result of PPD test in rheumatic patients,but has no influence on TSPOT results.The infection rate of latent tuberculosis of rheumatic patients in our research is 23.8%detected by TSPOT.